CN102753530B - 苯并氮杂*化合物 - Google Patents

苯并氮杂*化合物 Download PDF

Info

Publication number
CN102753530B
CN102753530B CN201080048410.3A CN201080048410A CN102753530B CN 102753530 B CN102753530 B CN 102753530B CN 201080048410 A CN201080048410 A CN 201080048410A CN 102753530 B CN102753530 B CN 102753530B
Authority
CN
China
Prior art keywords
compound
benzo
pharmaceutical composition
chloro
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080048410.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102753530A (zh
Inventor
菅庆三
大谷直明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Priority to CN201510199726.7A priority Critical patent/CN104829531A/zh
Publication of CN102753530A publication Critical patent/CN102753530A/zh
Application granted granted Critical
Publication of CN102753530B publication Critical patent/CN102753530B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Studio Devices (AREA)
CN201080048410.3A 2009-10-26 2010-10-25 苯并氮杂*化合物 Expired - Fee Related CN102753530B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510199726.7A CN104829531A (zh) 2009-10-26 2010-10-25 苯并氮杂*化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009245434 2009-10-26
JP2009-245434 2009-10-26
PCT/JP2010/068807 WO2011052519A1 (ja) 2009-10-26 2010-10-25 ベンズアゼピン化合物

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201410616974.2A Division CN104447555A (zh) 2009-10-26 2010-10-25 苯并氮杂*化合物
CN201510199726.7A Division CN104829531A (zh) 2009-10-26 2010-10-25 苯并氮杂*化合物

Publications (2)

Publication Number Publication Date
CN102753530A CN102753530A (zh) 2012-10-24
CN102753530B true CN102753530B (zh) 2015-06-17

Family

ID=43921941

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201080048410.3A Expired - Fee Related CN102753530B (zh) 2009-10-26 2010-10-25 苯并氮杂*化合物
CN201510199726.7A Pending CN104829531A (zh) 2009-10-26 2010-10-25 苯并氮杂*化合物
CN201410616974.2A Pending CN104447555A (zh) 2009-10-26 2010-10-25 苯并氮杂*化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201510199726.7A Pending CN104829531A (zh) 2009-10-26 2010-10-25 苯并氮杂*化合物
CN201410616974.2A Pending CN104447555A (zh) 2009-10-26 2010-10-25 苯并氮杂*化合物

Country Status (17)

Country Link
US (1) US8940727B2 (enExample)
EP (1) EP2495236A4 (enExample)
JP (1) JP5717645B2 (enExample)
KR (1) KR20120092139A (enExample)
CN (3) CN102753530B (enExample)
AU (1) AU2010312651A1 (enExample)
BR (1) BR112012009784A2 (enExample)
CA (1) CA2778756A1 (enExample)
CO (1) CO6481003A2 (enExample)
EA (1) EA022253B1 (enExample)
IL (1) IL219132A0 (enExample)
IN (1) IN2012DN03343A (enExample)
MX (1) MX2012004843A (enExample)
PH (1) PH12012500762A1 (enExample)
SG (1) SG10201406839VA (enExample)
WO (1) WO2011052519A1 (enExample)
ZA (1) ZA201202640B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
WO2019003433A1 (ja) 2017-06-30 2019-01-03 大塚製薬株式会社 ベンゾアゼピン誘導体
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
JP6868089B2 (ja) * 2018-12-28 2021-05-12 大塚製薬株式会社 医薬
CN112851583B (zh) * 2021-01-19 2023-09-08 徐州医科大学 新型苯并氮杂䓬类化合物、组合物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008049116A2 (en) * 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
WO2007143468A3 (en) * 2006-06-05 2008-11-27 Auspex Pharmaceuticals Inc Preparation and utility of substituted imidazopyridine compounds with hypnotic effects
WO2009001968A1 (en) * 2007-06-26 2008-12-31 Otsuka Pharmaceutical Co., Ltd. Benzazepine derivatives useful as vasopressin antagonists
JP2009502963A (ja) * 2005-07-29 2009-01-29 コンサート ファーマシューティカルズ インコーポレイテッド 新規なベンゾ［ｄ］［１，３］−ジオキソール誘導体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991005549A1 (en) 1989-10-20 1991-05-02 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
JP2905909B2 (ja) * 1991-04-19 1999-06-14 大塚製薬株式会社 バソプレシン拮抗剤
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5753677A (en) * 1989-10-20 1998-05-19 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
EP1097920B1 (en) 1993-07-21 2004-09-22 Yamanouchi Pharmaceutical Co. Ltd. Intermediate for condensed benzazepine derivatives
WO2009117144A1 (en) 2008-03-20 2009-09-24 Concert Pharmaceuticals, Inc. Benzazepine compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009502963A (ja) * 2005-07-29 2009-01-29 コンサート ファーマシューティカルズ インコーポレイテッド 新規なベンゾ［ｄ］［１，３］−ジオキソール誘導体
WO2007143468A3 (en) * 2006-06-05 2008-11-27 Auspex Pharmaceuticals Inc Preparation and utility of substituted imidazopyridine compounds with hypnotic effects
WO2008049116A2 (en) * 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
WO2009001968A1 (en) * 2007-06-26 2008-12-31 Otsuka Pharmaceutical Co., Ltd. Benzazepine derivatives useful as vasopressin antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Yoshitaka Yamamura er al..OPC-41061,a highly potent human vasopressin V2-receptor antagonist:pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.《the journal of pharmacology and experimental therapeutics》.1998,第287卷(第3期),860-867. *

Also Published As

Publication number Publication date
SG10201406839VA (en) 2014-12-30
US20130131045A1 (en) 2013-05-23
CO6481003A2 (es) 2012-07-16
MX2012004843A (es) 2012-05-29
WO2011052519A1 (ja) 2011-05-05
IN2012DN03343A (enExample) 2015-10-23
EA201290228A1 (ru) 2012-12-28
US8940727B2 (en) 2015-01-27
CN104447555A (zh) 2015-03-25
CN104829531A (zh) 2015-08-12
EP2495236A1 (en) 2012-09-05
IL219132A0 (en) 2012-06-28
BR112012009784A2 (pt) 2016-05-17
EA022253B1 (ru) 2015-11-30
ZA201202640B (en) 2013-06-26
PH12012500762A1 (en) 2012-11-26
CA2778756A1 (en) 2011-05-05
AU2010312651A1 (en) 2012-05-03
CN102753530A (zh) 2012-10-24
JPWO2011052519A1 (ja) 2013-03-21
EP2495236A4 (en) 2013-03-27
KR20120092139A (ko) 2012-08-20
JP5717645B2 (ja) 2015-05-13

Similar Documents

Publication Publication Date Title
US11186566B2 (en) Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EP2821401B1 (en) Dihydroquinolinone compounds as modulators of the muscarininc m1 receptor
TWI543974B (zh) 苯基－３－氮雜－雙環［３．１．０］己－３－基－甲酮及其作為藥物之用途
CN102753530B (zh) 苯并氮杂*化合物
CN101868453A (zh) Mdm2与p53间相互作用的抑制剂
CA2976369A1 (en) Biaryltriazole inhibitors of macrophage migration inhibitory factor
TWI798234B (zh) 苯并氮呯衍生物
US20210101868A1 (en) Substituted 3-Dialkylaminomethyl-Piperidin-4-yl-Benzamides and Methods of Making and Using Same
EP3083644B1 (en) 5-aryl-1-imino-1-oxo-[1,2,4]thiadiazines
KR20130044314A (ko) 제5형 포스포다이에스터라아제 억제용 화합물 및 그의 제조 방법
CN106458902B (zh) 吡啶衍生物
WO2019163865A1 (ja) 含窒素複素環を有するジベンゾアゼピン誘導体
WO2018139471A1 (ja) ジベンゾジアゼピン誘導体
HK1171751A (en) Benzazepine compound
EP2760871B1 (en) Oxy-cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists
HK40011778A (en) Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
HK40011778B (en) Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
HK1220204B (en) 5-aryl-1-imino-1-oxo-[1,2,4]thiadiazines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150617

Termination date: 20151025

EXPY Termination of patent right or utility model